Poorly differentiated round cell sarcomas present diagnostic challenges due to their variable morphology and lack of specific immunophenotypic markers. We present a case of a 15-year-old female with a tibial tumor that exhibited features of Ewing-like sarcoma, including apparent rearrangement of the EWSR1 gene. Hybridization capturebased next-generation DNA sequencing showed evidence of complex genomic rearrangements, absence of known pathogenic Ewing-like chromosome translocations, and deletions RB1, PTCH1, and ATRX, supporting the diagnosis of osteosarcoma. This illustrates the potential of clinical genomic profiling to improve diagnosis and enable specifically targeted therapies for cancers with complex pathologies.
INTRODUCTION
Conversely, round cell variants of osteosarcoma, Ewing sarcoma, peripheral neuroectodermal tumor, and myeloid leukemia can have indistinguishable morphologic appearance and share immunophenotypic markers, in spite of distinct molecular and genetic pathologies [3] . In particular, osteosarcomas are characteristically defined by complex genomic rearrangements, including chromothripsis, and inactivating mutations of TP53 and RB1 genes [4] . On the other hand, most Ewing sarcomas are genomically stable with low rates of aneuploidy and chromosomal copy number changes, infrequent mutations of TP53, and uniform chromosomal translocations of the EWSR1 gene [5] [6] [7] .
Cases of small cell osteosarcomas with EWSR1 rearrangements have been reported, but it is not known whether this is associated with Ewing-like sarcoma clinical behavior and therapy response, a question with potential therapeutic implications since treatment . CC-BY-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/039834 doi: bioRxiv preprint first posted online Feb. 17, 2016; regimens for osteogenic and Ewing sarcomas have significant differences [8] . Here, we describe a patient with a tibial tumor, who was found to have a round cell sarcoma with an apparent EWSR1 rearrangement, consistent with a diagnosis of Ewing-like sarcoma, but instead was diagnosed as osteosarcoma based on genomic profiling.
. CC-BY-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/039834 doi: bioRxiv preprint first posted online Feb. 17, 2016;
CASE DESCRIPTION
The patient is a 15-year-old female with an unremarkable past medical history who developed a slowly enlarging painful tibial mass. Radiography and magnetic resonance imaging revealed a heterogeneous mass in the metadiaphysis with periosteal reaction and extensive soft tissue extension. Plain radiography described the lesion as containing mixed lytic and sclerotic lesions. rearrangement and recent discovery of round cell Ewing-like sarcomas with CIC gene translocations without EWSR1 rearrangements [9] , FISH for CIC rearrangements was performed and found to be normal (not shown). Similarly, FISH analysis using custom BAC probes showed no rearrangements of the FLI1, ERG or NFATC2 genes [10] .
. CC-BY-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/039834 doi: bioRxiv preprint first posted online Feb. 17, 2016; Based on these histopathologic findings, a diagnosis of Ewing-like sarcoma was made, and neoadjuvant Ewing sarcoma-directed chemotherapy treatment was initiated with high-dose cyclophosphamide, doxorubicin, and vincristine [11] .
Given the atypical histopathologic tumor appearance and atypical FISH findings, the tumor specimen and matched peripheral blood cell genomic DNA were analyzed using hybridization capture-based next-generation DNA sequencing, specifically designed to identify mutations in 341 genes known to be pathogenically mutated in human cancers [12] . These results are detailed in Table 1 . Notably, we found numerous copy number changes, including homozygous segmental chromosomal deletions involving RB1, PTCH1, and ATRX, genes that are characteristically disrupted in osteosarcomas instead of Ewing sarcomas [13] [14] [15] . Additionally, the analysis demonstrated absence of genomic rearrangements affecting specific regions of the EWSR1 gene known to be involved in Ewing-like chromosomal translocations [12, 16] .
The high number of chromosomal alterations seen in this patients tumor is consistent with chromoplexy classically seen in osteosarcoma [13, 15] .
Given the presence of i) numerous genomic copy number changes, ii) mutations of genes characteristically disrupted in osteosarcomas, and iii) lack of Ewing-like chromosomal rearrangements, the patient's original diagnosis was reassessed. While genomically complex Ewing sarcomas have been observed, they are invariably associated with mutations of TP53 [5] . In this case, we found no pathogenic somatic or germ-line alterations of TP53. However, subsets of osteosarcoma have been found to exhibit TP53 rearrangements involving Alu intronic elements, which may evade 17, 2016; detection by targeted sequencing such as MSK-IMPACT [12, 17, 18] . At the time of this reassessment, the patient underwent definitive surgical resection, which demonstrated high-grade osteosarcoma with 80% cellular necrosis corroborating the conclusions of the molecular analysis. Given the definitive diagnosis of osteosarcoma, the patient completed consolidation therapy with osteosarcoma-directed treatment using high-dose methotrexate, doxorubicin, and cisplatin [11] . Consistent with the patient's remote family history of cancer, examination of patient's non-tumor DNA revealed no pathogenic germ-line variants. Variants of unknown significance in her germline included only PARP1 p.W481C, FOXP1 p.A15V, RECQL4 p.D1121N, and AMER1 p.E385Q.
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DISCUSSION
Poorly differentiated round cell sarcomas present significant diagnostic challenges due to their variable morphology and lack of specific immunophenotypic markers [3] . Genetic tests are increasingly being used to improve both the classification of disease in general and precision of diagnosis for individual patients. In this case, the diagnostic tumor specimen exhibited an apparent EWSR1 gene rearrangement and CD99 immunopositivity consistent with Ewing-like sarcoma. However, in addition to Ewing sarcomas, CD99 expression can be seen in synovial sarcomas and small cell osteosarcomas [8] . This case suggests that additional variants of osteosarcomas appear to express CD99. In addition, genomic instability and chromothripsis that characterize distinct tumors such as osteosarcoma can induce apparent gene rearrangements that are in and of themselves pathogenic [4, 19] . Hybridization capture- (Table 1) [12] . We suspect that similar genomic rearrangements are responsible for the apparent EWSR1 break-apart FISH signal ( Figure 1B) . In contrast to focused clinical genetic tests such as FISH, genomic profiling using next-generation DNA sequencing offers the ability to characterize genetic lesions genome-wide, with base-pair resolution necessary to confidently ascribe pathogenic functions. Indeed, clinical genomic profiling utilized in this case revealed deletions of genes characteristically inactivated in osteosarcomas, such as RB1, ATRX, and PTCH1 [13, 14] . Thus, genomic profiling enhanced clinical diagnosis, leading to more precise . 17, 2016; therapy selection, given substantial differences in current treatment regimens for osteogenic and Ewing sarcomas [11] . In this specific case, we identified somatic deletion of PTCH1, consistent with the prior observations of PTCH1 mutations in osteosarcomas, which cause activation of the Hedgehog signaling pathway and susceptibility to emerging targeted inhibitors of Hedgehog signaling such as vismodegib [20] . We anticipate that comprehensive use of clinical genomic profiling will lead to the identification of pathogenic lesions with specific therapeutic agents allowing for their rapid incorporation into precisely engineered treatment regimens, particularly for cancers with complex or atypical pathologies, similar to the one described here. 
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